GlassScriptPhysician profile
Morris Brooks Jackson
NPI 1477511921
$7,494.61
in general payments reported to CMS, 2019-2025
38 companies · $1,240 in 2025
The $1,240 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $976 · 2020: $849 · 2021: $1,066 · 2022: $1,091 · 2023: $719 · 2024: $1,553 · 2025: $1,240.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,478 · Education: $35.06.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,478.00 |
| Education | $35.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $2,114.73 | 2021-2025 | Interstim, Altaviva |
| Endo Pharmaceuticals INC. | $1,139.11 | 2019-2024 | Xiaflex, Aveed, Edex |
| Medtronic USA, INC. | $685.03 | 2019-2020 | |
| Endo USA, INC. | $456.83 | 2024-2025 | Xiaflex, Aveed |
| Sumitomo Pharma America, INC. | $445.04 | 2024-2025 | Gemtesa, Orgovyx |
| Astellas Pharma US INC | $278.01 | 2019-2022 | |
| Abbvie INC. | $243.98 | 2019-2025 | |
| Blue Earth Diagnostics | $211.45 | 2019-2021 | |
| Baxter Healthcare | $206.17 | 2021-2024 | Floseal |
| Merck Sharp & Dohme LLC | $181.07 | 2020-2025 | Welireg, Keytruda |
| Urogen Pharma, INC. | $164.69 | 2022-2025 | |
| Neotract INC. | $129.03 | 2020 | |
| Novartis Pharmaceuticals Corporation | $126.29 | 2020-2025 | |
| Siemens Medical Solutions USA, INC. | $116.63 | 2021 | |
| Ferring Pharmaceuticals INC. | $115.82 | 2019-2025 | Adstiladrin |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Antares Pharma, INC. | $95.17 | 2019-2022 | |
| Teleflex LLC | $94.04 | 2021 | |
| Procept Biorobotics Corporation | $92.92 | 2022-2023 | Aquabeam Robotic System |
| Astrazeneca Pharmaceuticals LP | $71.72 | 2025 | Lynparza, Imfinzi |
| Janssen Biotech, INC. | $51.66 | 2019-2024 | Erleada |
| Axonics, INC. | $49.04 | 2023 | Axonics |
| Urovant Sciences INC | $47.20 | 2021-2022 | |
| Tolmar, INC. | $40.14 | 2023-2024 | |
| Pfizer INC. | $39.45 | 2024-2025 | |
| Myriad Genetic Laboratories, INC. | $34.02 | 2024 | Prolaris |
| Boston Scientific Corporation | $31.47 | 2019 | |
| Coloplast Corp | $26.42 | 2019-2022 | |
| C. R. Bard, INC. & Subsidiaries | $25.21 | 2020 | |
| Accord Healthcare, INC. | $24.85 | 2024 | |
| Verity Pharmaceuticals INC. | $24.38 | 2025 | Tlando |
| Myovant Sciences INC. | $23.93 | 2021 | |
| Allergan, INC. | $22.50 | 2020 | |
| Hollister Incorporated | $21.35 | 2023 | Infyna Chic |
| Olympus America INC. | $18.34 | 2025 | Itind System |
| Progenics Pharmaceuticals, INC. | $15.19 | 2023 | Pylarify |
| Immunitybio, INC. | $13.70 | 2024 | |
| Pacira Pharmaceuticals Incorporated | $12.23 | 2022 | |
| Clarus Therapeutics INC. | $5.80 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Morris Jackson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.